MissionIR would like to highlight
Advaxis (
NASDAQ:ADXS), a clinical-stage biotechnology company. Advaxis is developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform technology using live, attenuated bacteria that are bio-engineered to secrete an antigen/adjuvant fusion protein that is designed to redirect the powerful immune response all human beings have to the bacterium to the cancer itself.
In the company’s news,
Advaxis announced that it will be presenting at the Biotech Showcase 2014 Conference in San Francisco, California. The conference will be taking place at the Parc 55 Wyndham San Francisco Union Square Hotel from Monday, January 13, 2014 to Wednesday, January 15, 2014.
Mr. Daniel J. O’Connor, the CEO of Advaxis, will be presenting a corporate update at 11:30 am PST (Pacific Time) on Wednesday, January 14, 2014. Aside from on-site attendance, onlookers can watch the presentation along with a slide presentation at: http://www.media-server.com/m/p/nzctmxk8.
Advaxis is a clinical-stage, publicly held biotechnology company that is focusing on developing next-generation cancer immunotherapies. All of the company’s immunotherapeutic innovations are based upon a unique platform using live, attenuated bacteria that secrete an antigen/adjuvant fusion protein(s). These proteins, in turn, are designed to redirect the powerful immune response all human beings have to the bacterium to a cancer itself. Currently, Advaxis has over 15 immunotherapies in various stages of development. The company’s lead drug candidate, ADXS-HPV, is in multiple clinical trials for HPV-related cancers.
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
To sign up for The MissionIR Report, please visit http://MissionIR.com
To connect with MissionIR via Facebook, please visit http://Facebook.com/MissionIR
To connect with MissionIR via Twitter, please visit http://Twitter.com/MissionIR
Please read FULL disclaimer on the MissionIR website: http://Disclaimer.MissionIR.com
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
